Pharmaceutical giant Johnson and Johnson said today (June 10, 2020) it will accelerate the development of its COVID-19 vaccine by launching human trials in late July instead of September, according to the Washington Times website.
The study will examine the investigational vaccine's safety and its ability to produce an immune response in more than 1,000 adults in the U.S. and Belgium.
J and J's chief scientific officer, Dr. Paul Stoffels, said its Janssen division sped up the timeline based on " the strength of the preclinical data we have seen so far and interactions with the regulatory authorities."
It wants to provide one billion doses globally through the course of 2021, provided the vaccine is safe and effective.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment